This clinical trial is focused on studying the effects of the medication nintedanib, also known by its code name BIBF 1120, in treating a rare condition called Unicentric Castleman Disease. This disease involves the overgrowth of cells in a single lymph node, which can cause various symptoms and complications. The trial will use two forms of the medication: Ofev 100 mg soft capsules and Ofev 150 mg soft capsules, both taken orally.
The purpose of the study is to evaluate how effective nintedanib is in reducing the size and activity of the affected lymph node over a period of six months. Participants will be monitored to see if there is a decrease in the activity of the disease, measured by a method called Total Lesion Glycolysis (TLG), which assesses how much energy the affected tissue is using. The study will also track any side effects or adverse events that occur during the treatment period.
Throughout the study, participants will undergo regular assessments to monitor changes in the disease and any potential complications. These assessments will include imaging tests and evaluations of lung function, as well as blood tests to measure the concentration of nintedanib in the body. The study aims to provide valuable information on the potential benefits and risks of using nintedanib for treating Unicentric Castleman Disease.
France 
